Lotte S. Mikkelsen

Copenhagen, Denmark

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 23 publications

Substitutions M478K and A482G in the polymerase of yellow fever virus confer resistance to sofosbuvir and uprifosbuvir in vitro.

Substitutions M478K and A482G in the polymerase of yellow fever virus confer resistance to sofosbuvir and uprifosbuvir in vitro.

Journal: Antiviral research
Published: October 07, 2025

Substitutions M478K and A482G in the polymerase of yellow fever virus confer resistance to sofosbuvir and uprifosbuvir in vitro.

Substitutions M478K and A482G in the polymerase of yellow fever virus confer resistance to sofosbuvir and uprifosbuvir in vitro.

Journal: Antiviral research
Published: October 07, 2025

SARS-CoV-2 Remdesivir Exposure Leads to Different Evolutionary Pathways That Converge in Moderate Levels of Drug Resistance.

SARS-CoV-2 Remdesivir Exposure Leads to Different Evolutionary Pathways That Converge in Moderate Levels of Drug Resistance.

Journal: Viruses
Published: June 19, 2025

In vivo and in vitro recombinant systems of a novel variant demonstrate cross-reactive neutralization for the HCV model virus, Norway rat hepacivirus.

In vivo and in vitro recombinant systems of a novel variant demonstrate cross-reactive neutralization for the HCV model virus, Norway rat hepacivirus.

Journal: PLoS pathogens
Published: September 23, 2024

Neutralizing antibody and CD8+ T cell responses following BA.4/5 bivalent COVID-19 booster vaccination in adults with and without prior exposure to SARS-CoV-2.

Neutralizing antibody and CD8+ T cell responses following BA.4/5 bivalent COVID-19 booster vaccination in adults with and without prior exposure to SARS-CoV-2.

Journal: Frontiers in immunology
Published: December 10, 2023

Differential activity of nucleotide analogs against tick-borne encephalitis and yellow fever viruses in human cell lines.

Differential activity of nucleotide analogs against tick-borne encephalitis and yellow fever viruses in human cell lines.

Journal: Virology
Published: March 04, 2023

Durability and breadth of neutralisation following multiple antigen exposures to SARS-CoV-2 infection and/or COVID-19 vaccination.

Durability and breadth of neutralisation following multiple antigen exposures to SARS-CoV-2 infection and/or COVID-19 vaccination.

Journal: EBioMedicine
Published: November 12, 2022

Characterization of multi-DAA resistance using a novel hepatitis C virus genotype 3a infectious culture system.

Characterization of multi-DAA resistance using a novel hepatitis C virus genotype 3a infectious culture system.

Journal: Hepatology (Baltimore, Md.)
Published: September 18, 2022

Identification of the viral and cellular microRNA interactomes during SARS-CoV-2 infection.

Identification of the viral and cellular microRNA interactomes during SARS-CoV-2 infection.

Journal: Cell reports
Published: May 12, 2022

Versatile SARS-CoV-2 Reverse-Genetics Systems for the Study of Antiviral Resistance and Replication.

Versatile SARS-CoV-2 Reverse-Genetics Systems for the Study of Antiviral Resistance and Replication.

Journal: Viruses
Published: December 01, 2021

Analysis of Neutralization Titers against SARS-CoV-2 in Health-Care Workers Vaccinated with Prime-Boost mRNA-mRNA or Vector-mRNA COVID-19 Vaccines.

Analysis of Neutralization Titers against SARS-CoV-2 in Health-Care Workers Vaccinated with Prime-Boost mRNA-mRNA or Vector-mRNA COVID-19 Vaccines.

Journal: Vaccines
Published: November 14, 2021

Neutralisation titres against SARS-CoV-2 are sustained 6 months after onset of symptoms in individuals with mild COVID-19.

Neutralisation titres against SARS-CoV-2 are sustained 6 months after onset of symptoms in individuals with mild COVID-19.

Journal: EBioMedicine
Published: April 30, 2021
Showing 1-12 of 23

Last Updated: 09/26/2026